[Federal Register Volume 78, Number 139 (Friday, July 19, 2013)]
[Notices]
[Pages 43219-43220]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2013-17318]
[[Page 43219]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive License: Live Attenuated Dengue
Tetravalent Vaccine Containing a Common 30 Nucleotide Deletion in the
3'-UTR of Dengue Types 1, 2, 3, and 4
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is notice, in accordance with 35 U.S.C. 209 and 37 CFR
Part 404, that the National Institutes of Health (NIH), Department of
Health and Human Services (HHS), is contemplating the grant of a an
exclusive license to practice the following invention as embodied in
the following patent applications: (1) E-120-2001/0, Whitehead et al.,
``Development of Mutations Useful for Attenuating Dengue Viruses and
Chimeric Dengue Viruses'', European Patent Application Number
02739358.6 (now European Patent Number 1402075, validated in Austria,
Belgium, Switzerland/Liechtenstein, Germany, Denmark, Spain, Finland,
France, the United Kingdom, Ireland, Italy, the Netherlands, Sweden and
Turkey), filed May 22, 2002, United States Patent Application Number
10/719,547 (now U.S. Patent Number 7,226,602), filed November 21, 2003,
Canadian Patent Application Number 2448329 (now Canadian Patent Number
2448329), filed May 22, 2002, Australian Patent Application Number
20022312011 (now Australian Patent Number 20022312011), filed May 22,
2002, Australian Patent Application Number 2008203275 (now Australian
Patent Number 2008203275), filed May 22, 2002, Australian Patent
Application Number 2012200637, filed May 22, 2002, United States Patent
Application Number 11/446,050, filed June 2, 2006, now U.S. Patent
Number 7,560,118, issued July 14, 2009, United States Patent
Application Number 12/396,376 (now United States Patent Number
8,039,003), filed March 2, 2009, United States Patent Application
Number 13/240,849, filed September 22, 2011, European Patent
Application Number 10181776.5, filed May 22, 2002, European Patent
Application Number 10181786.4, filed May 22, 2002, and European Patent
Application Number 10181804.5, filed May 22, 2002 (2) E-089-2002/0,1,
Whitehead et al., ``Dengue Tetravalent Vaccine Containing a Common 30
Nucleotide Deletion in The 3'-UTR of Dengue Types 1,2,3, And 4, or
Antigenic Chimeric Dengue Viruses 1,2,3, And 4'', United States Patent
Application Number 10/970,640 (now United States Patent Number
7,517,531), filed October 21, 2004, Canadian Patent Application Number
2483653, filed April 25, 2003, European Patent Application Number
03724319.3 (now European Patent Number 1554301, validated in Austria,
Belgium, Bulgaria, Switzerland/Liechtenstein, Estonia, Finland, France,
the United Kingdom, Ireland, Iceland, Italy, Lithuania, Malta, the
Netherlands, Poland, Portugal, Romania, Sweden, Slovenia, Slovakia,
Turkey, Cyprus, Croatia, Czech Republic, Denmark, Germany, Greece,
Hungary, Latvia, Luxembourg, and Monaco), filed April 25, 2003,
Japanese Patent Application Number 2004-50077, filed April 25, 2003,
Australian Patent Application 2003231185 (now Australian Patent Number
2003231185), filed April 25, 2003, United States Patent Application
Number 12/398,043 (now United States Patent Number 8,075,903), filed
March 4, 2009, United States Patent Application Number 13/305,639,
filed November 28, 2011, European Patent Application Number 10177735.7,
filed April 25, 2003, and European Patent Application Number
10177740.7, filed April 25, 2003, and (3) E-139-2006/0, Whitehead et
al., ``Development of Dengue Vaccine Components'', Australian Patent
Application 2007285929, filed August 15, 2007, Canadian Patent
Application Number 2661296, filed August 15, 2007, Chinese Patent
Application Number 200780031489.4, filed August 15, 2007, European
Patent Application Number 07840969.5, filed August 15, 2007, United
States Patent Application Number 12/376,756 (now U.S. Patent Number
8,337,860), filed February 6, 2009, and United States Patent
Application Number 13/692,557, filed December 3, 2012 to Merck Sharp &
Dohme Corp., having a place of business in Whitehouse Station, New
Jersey, U.S.A. The patent rights in this invention have been assigned
to the United States of America.
DATES: Only written comments and/or application for a license which are
received by the NIH Office of Technology Transfer on or before August
19, 2013 will be considered.
ADDRESSES: Requests for a copy of the patent application, inquiries,
comments and other materials relating to the contemplated license
should be directed to: Peter Soukas, Office of Technology Transfer,
National Institutes of Health, 6011 Executive Boulevard, Suite 325,
Rockville, MD 20852-3804; Email: [email protected]; Telephone: (301) 435-
4646; Facsimile: (301) 402-0220.
SUPPLEMENTARY INFORMATION: The global prevalence of dengue has grown
dramatically in recent decades. The disease is now endemic in more than
100 countries in Africa, North and South America, the Eastern
Mediterranean, Southeast Asia and the Western Pacific. Southeast Asia
and the Western Pacific are most seriously affected. Before 1970 only
nine countries had experienced Dengue Hemorrhagic Fever (DHF)
epidemics, a number that had increased more than four-fold by 1995. WHO
currently estimates there may be 50 million cases of dengue infection
worldwide every year.
The methods and compositions of this invention provide a means for
prevention of dengue infection and dengue hemorrhagic fever (DHF) by
immunization with attenuated, immunogenic viral vaccines against
dengue. The vaccine is further described in Blaney JE et al.,
``Mutations which enhance the replication of dengue virus type 4 and an
antigenic chimeric dengue virus type \2/4\ vaccine candidate in Vero
cells.'' Vaccine. 2003 Oct 1;21(27-30):4317-27 and Whitehead SS et al.,
``A live, attenuated dengue virus type 1 vaccine candidate with a 30-
nucleotide deletion in the 3' untranslated region is highly attenuated
and immunogenic in monkeys.'' J. Virol. 2003 Jan;77(2):1653-7.
The prospective exclusive license will be royalty bearing and will
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR Part
404. The prospective exclusive license may be granted unless, within
thirty (30) days from the date of this published Notice, NIH receives
written evidence and argument that establishes that the grant of the
license would not be consistent with the requirements of 35 U.S.C. 209
and 37 CFR 404.
The field of use may be limited to live attenuated vaccines against
dengue infections in humans.
Properly filed competing applications for a license filed in
response to this notice will be treated as objections to the
contemplated license. Comments and objections submitted in response to
this notice will not be made available for public inspection, and, to
the extent permitted by law, will not be released under the Freedom of
Information Act, 5 U.S.C. 552.
[[Page 43220]]
Dated: July 15, 2013.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 2013-17318 Filed 7-18-13; 8:45 am]
BILLING CODE 4140-01-P